A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of HSK29116 in patients with advanced B-cell malignancies.

Timeline

Start

2021-08-24

Primary completion

2023-08

Completion

2023-10

Drugs

Indications